$2.38
-0.18 (-7.03%)
Open$2.53
Previous Close$2.56
Day High$2.53
Day Low$2.34
52W High$8.80
52W Low$1.96
Volume—
Avg Volume237.8K
Market Cap109.82M
P/E Ratio—
EPS$-28.45
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+69.3% upside
Current
$2.38
$2.38
Target
$4.03
$4.03
$3.03
$4.03 avg
$5.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.71M | 21.78M | 21.76M |
| Net Income | 4.38M | 3.81M | 4.44M |
| Profit Margin | 20.2% | 17.5% | 20.4% |
| EBITDA | 6.15M | 6.17M | 6.37M |
| Free Cash Flow | 3.82M | 4.48M | 4.63M |
| Rev Growth | +1.1% | -8.2% | +18.1% |
| Debt/Equity | 0.50 | 0.50 | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |